Agoracom Blog Home

Posts Tagged ‘CBD’

« Older Entries
Newer Entries »

Hollister Biosciences $HOLL.ca Provides Update on Q2 2020, Generated Record Quarterly Revenue of CDN$ 11.5 Million and Announces Distribution License Renewal $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:05 PM on Tuesday, July 14th, 2020
  • Generated record quarterly revenue of CDN$ 11.5 million,
  • CDN$ 1.375 million in EBITDA
  • Bureau of Cannabis Control officially renewed its cannabis distribution license for the next year through August 2021

VANCOUVER, BC, July 14, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona,  is pleased to provide an update on its Q2, 2020 performance as well as announce that the Bureau of Cannabis Control (“BCC“) officially renewed its cannabis distribution license for the next year through August 2021.

Q2 2020 Update

For the period beginning April 1st, 2020 and ending June 30th, 2020, Hollister reports that it generated record quarterly revenue of CDN$ 11.5 million and CDN$ 1.375 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products.  The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.

“We are very pleased with our revenue growth year to date.  Sales of cannabis related products have proven to be resilient throughout the COVID-19 pandemic.  We hope to continue to deliver strong results as the year progresses” stated Carl Saling, CEO.

About the BCC

The Bureau of Cannabis Control is the lead agency in regulating commercial cannabis licenses for medical and adult-use cannabis in California. The BCC is responsible for licensing retailers, distributors, testing laboratories, microbusinesses, and temporary cannabis events. A distributor (Type 11) licensee is responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, and conducting the quality assurance review of cannabis goods to ensure compliance with all packaging and labeling requirements. A licensed distributor may only distribute cannabis goods, cannabis accessories, and licensees’ branded merchandise or promotional materials.

“Our distribution license is a critical component to our California operation, and we are honored to have had our license renewed by the BCC” stated Carl Saling, CEO.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Tags: , , , , ,
Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Provides Update on Q2 2020, Generated Record Quarterly Revenue of CDN$ 11.5 Million and Announces Distribution License Renewal $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

The Power of Psychedelics SPONSOR: MOTA Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:40 AM on Monday, July 13th, 2020

SPONSOR: Mota Ventures Corp is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Mota is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here for More Info

In 2012, I had my first psychedelic experiences, as a subject in a clinical trial at Johns Hopkins University School of Medicine’s Behavioral Pharmacology Research Unit. I was given two doses of psilocybin spaced a month apart to treat my cancer-related depression.

During one session, deep within the world the drug evoked, I found myself inside a steel industrial space. Women were bent over long tables, working. I became aware of my animosity towards my two living siblings. A woman seated at the end of a table wearing a net cap and white clothes, turned and handed me a tall Dixie cup.

“You can put that in here,” she said. The cup filled itself with my bilious, sibling-directed feelings. “We’ll put it over there.” She turned and placed the cup matter-of-factly on a table at the back of the room. Then she went back to her tasks.

Whenever I speak with her, Mary Cosimano, the director of guide/facilitator services at Johns Hopkins Center for Psychedelic and Consciousness Research, mentions the women in the chamber and the cup. My experience struck a chord. For me, the women in the chamber have become a transcendent metaphor for emotional healing.

“I’ve thought about having a necklace made, with the cup, as a momento,” she said the last time I saw her at a conference. “Have you thought about it?”

Prior to their 1971 prohibition, psilocybin and LSD were administered to approximately 40,000 patients, among them people with terminal cancer, alcoholics and those suffering from depression and obsessive-compulsive disorder. The results of the early clinical studies were promising, and more recent research has been as well.

The treatment certainly helped me. Eight years after my sessions, researchers continue to prove the same point again and again in an ongoing effort to turn psychedelic drug therapy into FDA-sanctioned medical treatment. This can’t happen soon enough.

“Psychopharmacology as a field had stalled. Many patients don’t respond to conventional treatment with SSRIs,” says Charles Grob, M.D., professor of psychiatry and biobehavioral Sciences at Harbor-UCLA Medical Center, and the first modern clinical researcher to treat advanced-stage cancer patients suffering from depression and anxiety with psychedelics.

There is little hard evidence to show that long-term psychotherapy is effective in treating mental illness, depression or post-traumatic stress disorder (PTSD). And there’s the cost, which fewer and fewer insurers underwrite and ordinary people can’t afford.

The failure of the psychotherapeutic process is located at its epicenter: the power disparity in the therapeutic dyad. Merely walking through the consulting room door, the patient subordinates herself to the therapist, who, by virtue of a title, is presumed to know more about her than she does herself. Transference and countertransferance—offspring of Freudian psychoanalysis—are cogs in the same moribund engine. The field will not change until the therapeutic relationship as it has been structured since the 19th century disappears.

Psychedelic drug therapy subverts the timeworn patriarchal hierarchy by creating an atmosphere of cooperation and trust rather than competition and domination. Or, to state it more bluntly, what women do in structured settings rather than what men do; women create cooperatives, men create hierarchies.

The treatment space is furnished like a lounge, with couches, chairs and table lamps. A music track plays. Two trained guides, one male, one female, are seated close by, ready to help if the emotional path becomes difficult. Guides are not therapists; instead they serve as trusted companions along a perilous, transformative spiritual journey. The sessions are led by the subject herself, by her feelings and perceptions throughout the experience and the way she processes them afterward.

“The drug is a skeleton key which unlocks an interior door to places we don’t generally have access to,” says psychologist William A. Richards, one of the researchers who successfully treated patients with hallucinogens in the 1960s and early 1970s. “It’s a therapeutic accelerant.”

MDMA (3,4-methylenedioxymethamphetamine) is rapidly proving effective in treating PTSD. MDMA is an “entactogen”: it touches within in a way talking does not. Michael Mithoefer, a psychiatrist in Charleston, S.C., who has worked with military personnel and first responders, conducted a phase II clinical trial using MDMA to treat PTSD.

“[Treatment is] not just revisiting the traumatic experiences,” he said. “It’s a process of affirming a different experience on all levels, including in the body.”

During MDMA sessions, subjects become more emotionally flexible and able to stay the course while exploring difficult memories. Many experience an enduring change in their response to emotional triggers. Clinicians hope to see MDMA approved by the FDA for PTSD treatment as early as 2022.

Treatment with psychedelic drugs represents a paradigm shift in the approach to mental health. For me, the change in the field is embodied by the presence of the busy women along my journey. The women treated my feelings as matters of fact, not to be avoided, reviled or fled from, but so obvious and ordinary they could be poured into a Dixie cup and set aside.

The success of the cancer studies has led to investigational treatment for patients suffering from intractable depression, early-stage Alzheimer’s, anorexia nervosa and smoking addiction. Within a few years, the patriarchal therapeutic model could be a thing of the past, supplanted by short-term guided treatment with psychoactive drugs.

SOURCE:https://www.scientificamerican.com/article/the-power-of-psychedelics/

Tags: , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on The Power of Psychedelics SPONSOR: MOTA Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

INTERVIEW: TransCanna $TCAN.ca License Creates One Of California’s Largest Fully Licensed Cannabis Facilities $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:12 PM on Sunday, July 12th, 2020
tcan-square

TransCanna Holdings (TCAN:CSE) is part of the New Cannabis Kids On The Block wave that investors are demanding after mega financed companies flopped last year.  TCAN, on the other hand, is delivering the following to investors: 

·  $2M CAD Revenue April 2020 

·  $24.6M CAD Revenue Run Rate solely from TransCanna test facility 

·  $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021 

·  Daly facility will be one of the largest cannabis facilities in California 

And today the story got even better, with TCAN announcing that its wholly-owned subsidiary was granted a “Type 11 Distributor License” by the California Bureau of Cannabis Control for its 196,000 square foot Daly Avenue Facility. 

HUGE BUSINESS IMPLICATIONS – TRANSCANNA POSITIONED TO BECOME PART OF NEW LEADERSHIP GROUP IN CANNABIS  

As a result, Trancanna now owns the largest known, fully licensed cannabis facility in California.  Given the fact TCAN is processing more than $USD 1,000,000/month in wholesale cannabis transactions out of a distribution space of just 1,000 square feet, the implications for Daly expanding to 196,000 square feet are HUGE in the areas of:  

  • Capacity 
  • Revenue
  • Reach
  • …. much more 

The first round of cannabis leaders disappointed investors and created significant value destruction in the space.  But like every new mega industry that goes through a catharsis stage, the next round of growth gives birth to the best and potentially biggest players for the long haul.

The next 24 – 36 months are going to be fun for TCAN.  How fun?  Watch this interview with CEO Bob Blink.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, TransCanna Holdings Inc. | Comments Off on INTERVIEW: TransCanna $TCAN.ca License Creates One Of California’s Largest Fully Licensed Cannabis Facilities $CGC $ACB $APH $CRON.ca $OGI.ca

TransCanna Receives State-Wide Operating License $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:49 PM on Sunday, July 12th, 2020
tcan-square
  • Successfully granted a Type 11 ‘Distributor’ license by the California Bureau of Cannabis Control for its 196,000 square foot Daly Avenue Facility
  • Now owns largest known fully licensed cannabis facilities in California
  • “This is the most exciting development in our history and what everyone has been working towards,” says Bob Blink, TransCanna CEO

Vancouver, British Columbia–(July 11, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: XETR) (“TransCanna” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Lyfted Farms, Inc. (“Lyfted”), was successfully granted a Type 11 ‘Distributor’ license by the California Bureau of Cannabis Control for its 196,000 square foot Daly Avenue Facility.

This long-anticipated milestone marks the completion of all state and local licenses required for the Company to begin operations at its flagship cannabis processing facility in Modesto, California.

This state-wide license represents Lyfted’s most major milestone to date in meeting the distribution and production capabilities needed to meet the escalating demand for its products in the world’s largest cannabis market. The license was granted after three levels of approvals were achieved at the county and state level and will allow for the commencement of packaging, transport, wholesale, pre-roll assembly, labeling, testing, contract packaging (white-labeling), and of course distribution of cannabis products to all licensed retailers across the state.

“This is the most exciting development in our history and what everyone has been working towards,” says Bob Blink, TransCanna CEO. “Being granted a license at the state level is a long, costly, and complex process, and one that requires navigating and understanding a complex regulatory process. It’s a significant barrier to entry for most companies, so this marks a huge turning point for us. We are delighted to have achieved our biggest goal to date and excited to be able to better serve the demands of the California cannabis market.”

The Company is currently completing upgrades to the flagship Daly Facility. Commercial cannabis activities are expected to commence at Daly August 2020, via the deployment of a 16,000 square foot cannabis distribution center (Phase 1). To date, Lyfted has been able to process in excess of $1M USD/month in wholesale cannabis transactions out of a distribution space of 1,000 square feet from its Jerusalem Court facility. These upgrades will mean the Company now has 16,000 square feet of distribution space at its disposal as of August 2020.

“This exponential increase in capacity is incredibly exciting for investors,” says Blink, adding the Company has been focused on building out its wholesale and distribution business while awaiting its final license. “Having processed a million dollars’ worth of product out of a single one-thousand square foot facility, we are anticipating significant growth now that our 196,000 square foot operation is online.”

Lyfted anticipates hiring up to 250 full-time employees at the flagship site with a strong focus placed on social equity and a diverse workforce that is reflective of the communities it serves and operates in.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors

Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Tags: , , , ,
Posted in Featured, TransCanna Holdings Inc. | Comments Off on TransCanna Receives State-Wide Operating License $CGC $ACB $APH $CRON.ca $OGI.ca

Mota Ventures $MOTA.ca Reports $7.65m Revenue in Q1 2020 $SHRM $RVV $APH.ca $GBLX $PFE $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 8:07 AM on Wednesday, July 8th, 2020

VANCOUVER, BC / ACCESSWIRE / July 8, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is pleased to announce its financial results for the first quarter ending March 31, 2020. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. The press release is intended to be read in conjunction with the Company’s unaudited Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis for the three months ended March 31, 2020, which are filed under the Company’s profile on SEDAR (www.sedar.com), and also available on the Company’s website.

First Quarter 2020 Key Highlights include:

  • The Company acquired online cannabidiol (CBD) product distributor Nature’s Exclusive from Unified Funding, LLC.
  • Agreement finalized with Sativida OU (Estonia) and Sativida OU’s subsidiary, VIDA BCN LABS S.L (collectively, “Sativida”) to acquire Sativida in stages.
  • The Company acquired the intellectual property and trade names of Sativida in Spain, which will be licensed back in exchange for a royalty associated with gross revenues generated by Sativida.
  • The Company entered into a Licensing and Royalty Agreement with Phenome One Corporation (“Phenome”) for the right to cultivate, harvest, process and sell a selection of cultivars from Phenome’s genetic library, and the Company was granted unlimited access to a Phenome’s proprietary nutrient intellectual property (IP) and catalogue.
  • The Company entered into a Joint Venture with BevCanna Enterprises Inc (“BevCanna”) to distribute BevCanna branded beverage products infused with hemp-derived CBD in the European market.
  • Consolidated Q1 2020 gross revenue was $7.65 million, with cost of goods sold of $7.05 million, resulting in gross profits of $605,150. Operating and other operating expenses for the three months ended March 31, 2020 were $5.24 million.
  • The Company raised $1.72 million through share subscriptions received for the issuance of units at $0.28 and received $309,000 in proceeds from the exercise of warrants.
  • The Company ended Q1 2020 with $2.1 million in cash.

Management Commentary

“In the midst of evolving challenges resulting from the global novel coronavirus outbreak, the Company realigned priorities to include focus on the health and safety of our employees, customers and suppliers. The way our team adapted and performed was exceptional. I am also pleased to announce that, despite the unprecedented uncertainties resulting from the coronavirus, our operations and supply chains performed without interruption, and the Company achieved targets in line with expectations. In order to capitalize on the global market, we recognize the need to be flexible and proactive in addressing market trends. For the second quarter our objectives are to yield increased revenues and higher gross margins. Due to the initial cost of customer acquisition, transitioning more customers into our monthly subscription will significantly increase margins.” stated Ryan Hoggan CEO of the Company.

About Mota Ventures Corp.

Mota Ventures is an established natural health products and eCommerce technology company focusing on the CBD and psychedelic medicine sectors. The company has a strong presence in both North America and Europe. In the United States, Mota Ventures offers a CBD hemp-oil product line derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, the company’s Verrian operations is currently conducting clinical studies utilizing proprietary products for the treatment of opiate addiction. The highly skilled Verrian team also manages Mota Ventures’ 110,000 square foot manufacturing facility in Radebeul, Germany. In addition, Mota Ventures’ Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. The company is also seeking to acquire additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its eCommerce technology platform.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Reports $7.65m Revenue in Q1 2020 $SHRM $RVV $APH.ca $GBLX $PFE $WEED.ca $HIP.ca $WMD.ca

Empower Clinics $CBDT.ca – 5 positive testimonials on medical marijuana benefits from real patients $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:30 PM on Monday, July 6th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic
  • Commenced tele-medicine services for patients, both in-clinics and virtually through secure video, on browser and in mobile app
  • Successfully conducted COVID-19 antibody business employee testing, solidifying the importance of phase three of the testing program
  • Conducted 2,302 physician-patient consultations setting a new milestone in patient volume for the month of May

—————————

5 positive testimonials on medical marijuana benefits from real patients

By: Pearce Thompson

We’d like to shine a light on a few patients in this article, to share their insights and experiences on how medical marijuana has benefited them throughout their illness. Please take the time to read through the list of 5 testimonials from real patients who have had positive outcomes from using the herb for their treatments.

If you want to view the history of medical marijuana referenced above, click here. If you want a timeline of the history of medical marijuana use in Canada, click here.

#1 Rebecca Swell an advocate of medical marijuana

When Rebecca was 10 years old she was diagnosed with Complex Regional Pain Syndrome, this condition comes from damage to the nervous system and causes extreme pain. Rebecca was forced into a walker or wheelchair from a young age, and when spinal cord stimulation and morphine didn’t work, she tried medical marijuana. Rebecca now needs no walking support, no morphine, and is an advocate of medical marijuana.

#2 Charlotte Figgi (Charlotte’s Web)

The story of Charlotte Figgi is more well known than most. Charlotte was diagnosed with a rare form of epilepsy at a young age and at 5 she experienced close to 300 mal seizures per week. The condition was so bad the doctor put her in a medically induced coma. In the first week of trying cannabis oil, Charlotte had no seizures. The strain created for her has no psychoactive effects and was renamed “Charlotte’s Web“.

#3 Ashley Surin

Ashly was diagnosed with Acute Lymphoblastic Leukemia, a type of cancer that affects white blood cells which makes it harder to fight infections. Ashley was also prone to seizures and her family moved to cannabis oil to aid this. The oil proved effective and is still used by Ashley to this day.

#4 Walter Rodlund

Walter Rodlund is from Fargo, ND and at the age 81 he enjoyed spending time outdoors his entire life. At this time he was diagnosed with Chronic Obstructive Pulmonary Disease, which decreased his lung capacity. With this condition, Walter could no longer enjoy the outdoors. His daughter recommended cannabis oil, Walter tried, Walter liked, Walter enjoys the outdoors again.

5. Beyla Pagano benefitted a lot by taking medical marijuana

From birth, Beyla had a large amount of cerebrospinal fluid built up in her brain. This caused seizures and doctors believed she would never walk or talk. The prescriptions given to her always put her in a drowsy state, so her family tried medical marijuana. The cannabis oil immediately improved her state, Beyla can walk, talk, and has seizures less frequently.

Tags: , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – 5 positive testimonials on medical marijuana benefits from real patients $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Empower $CBDT.ca #Covid19 Testing to Expand to Five Days Per Week and June 2020 Patient Visits Set Records $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:23 AM on Friday, July 3rd, 2020
  • Empower is expanding its COVID-19 testing to five days per week to meet demand
  • June 2020 patient volume surpasses 2,100 patients visits, a company record for the month of June

VANCOUVER, BC / July 3rd, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a life sciences company, is pleased to announce the Company is expanding COVID-19 testing days to meet the increasing demand in the State of Arizona. In addition, the Company conducted 2,130 physician-patient consultations setting a new historic milestone in patient volume for the month of June.

“As a company and a health & wellness clinic operator, we are fortunate to be able to provide care and support to our thousands of patients each month.” said Steven McAuley, Chairman & CEO of Empower. “The demand for our services, are at an all-time high, requiring us to hire new staff and extend hours of operation. Our team continues to perform with complete professionalism, and safety, knowing the importance of the physician consultations we provide.”

The Arizona Department of Health Services has reported that in the last seven (7) days, nearly 25,000 positive cases of coronavirus have been reported, representing more than 25% of the total cases in the state of Arizona since the pandemic first started in late January 2020. Total reported cases now exceed 87,000 in the state.

As previously disclosed, the Company submitted an application for a management cease trade order (“MCTO“) with the British Columbia Securities Commission. The Company confirms that the BC Securities Commission has approved the application for the MCTO effective June 16, 2020

As required under section 9 b) of the National Policy 12-203 – Cease Trade Orders the Company indicates it is unable to meet the prescribed filing deadline due to additional audit requirements by its auditor MNP, LLP and due to increased operational limitations related to the coronavirus pandemic. The Company continues to expect to file the annual filings, no later than July 15, 2020.

The Company intends to comply with the provisions of the alternative information guidelines as set out in the National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults for as long as it remains in default, including the issuance of bi-weekly default status reports, each of which will be issued in the form of a news release.

As required under Canadian securities laws, the Company will provide a further update on or about July 14, 2020. Additionally, to the knowledge of the Company, there have been no material business developments as of the date of this news release that have not been generally disclosed.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower $CBDT.ca #Covid19 Testing to Expand to Five Days Per Week and June 2020 Patient Visits Set Records $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Spyder Cannabis $SPDR.ca Announces Receipt of RSA (“Retail Store Authorization”) for its Niagara Falls dispensary $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:56 AM on Tuesday, June 30th, 2020
  • Further to the announcement of receipt of a Retail Operator License (“ROL”), the Company is pleased to announce the receipt of its Retail Store Authorization (” RSA”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane
  • The Company plans to begin operations at the location in July once the pre-opening inspection is completed, while ensuring it complies with COVID 19 provincial regulations and focusing on its curbside pickup and delivery business

Vaughan, Ontario–(June 30, 2020) –  Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company”) and its wholly-owned associated applicants, The Green Spyder Inc. and Spyder Cannabis Subco Inc., is pleased to provide the following update:

Niagara Falls Cannabis Dispensary

Further to the announcement of receipt of a Retail Operator License (“ROL”), the Company is pleased to announce the receipt of its Retail Store Authorization (” RSA”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane. The Company plans to begin operations at the location in July once the pre-opening inspection is completed, while ensuring it complies with COVID 19 provincial regulations and focusing on its curbside pickup and delivery business.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of Hemp CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain ‘forward-looking information” within the meaning of applicable securities laws (‘forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: [email protected]

Tags: , , , , ,
Posted in Featured, Spyder Cannabis Inc. | Comments Off on Spyder Cannabis $SPDR.ca Announces Receipt of RSA (“Retail Store Authorization”) for its Niagara Falls dispensary $CGC $ACB $APH $CRON.ca $OGI.ca

TransCanna $TCAN.ca Settles $39M Lawsuit with Pacific Agriculture LLC $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:07 AM on Tuesday, June 30th, 2020
tcan-square
  • Announced that it has entered into a General Release Agreement with Pacific Agriculture LLC, settling the claims in the lawsuit filed by Pacific Agriculture LLC in the New York State Supreme Court, Nassau County on November 25th, 2019
  • Pursuant to the terms of the General Release Agreement, TransCanna will pay a sum of US$50,000 to Pacific Agriculture LLC, and the pending litigation will be dismissed with prejudice

Vancouver, British Columbia–(June 30, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company“) is pleased to announce that it has entered into a General Release Agreement with Pacific Agriculture LLC, settling the claims in the lawsuit filed by Pacific Agriculture LLC in the New York State Supreme Court, Nassau County on November 25th, 2019.

Pursuant to the terms of the General Release Agreement, TransCanna will pay a sum of US$50,000 to Pacific Agriculture LLC, and the pending litigation will be dismissed with prejudice. Each party is responsible for its own costs, expenses, and attorneys’ fees.

“I’m proud of our team for holding our ground and defending our shareholder’s interests,” stated Bob Blink, CEO of TransCanna. “We are pleased with the outcome and believe that getting this resolved and alleviating any concerns is a huge step in the right direction. The company is firing on all cylinders, and we look forward to announcing more positive news in the coming weeks.”

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES DESCRIBED HEREIN

Tags: , , , ,
Posted in Featured, TransCanna Holdings Inc. | Comments Off on TransCanna $TCAN.ca Settles $39M Lawsuit with Pacific Agriculture LLC $CGC $ACB $APH $CRON.ca $OGI.ca

Hollister Biosciences Inc. $HOLL.ca and Allied Corp. sign Definitive Agreement for Distribution of Products Under Veteran Based Brand: Tactical Relief™ $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:12 AM on Friday, June 26th, 2020
  • Announced definitive agreement with Allied Corp. to manufacture and distribute throughout California products targeted at veterans and first responders under the brand Tactical Relief ™
  • The first products to be manufactured will feature products that are recognized for their medicinal properties in the treatment of Post Traumatic Stress Disorder (PTSD)

VANCOUVER, British Columbia, June 26, 2020 — Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB) (the “Company” or “Hollister”) is pleased to announce that further to the press release dated February 7th, 2020, through it’s subsidiary, Hollister Cannabis Co.  has on June 22nd, 2020 signed a definitive agreement (the “Agreement”) to bring to market with Allied Corp. (“Allied”) a pipeline of products that are targeted towards helping veterans and first responders. These products will be brought to market under the brand Tactical Relief™, a veteran-founded hemp-based CBD oil brand owned by Allied Corp. (OTCQB: ALID).

Branded under Tactical Relief™, the first products to be manufactured will feature products that are recognized for their medicinal properties in the treatment of Post Traumatic Stress Disorder (PTSD). True to Hollister’s mission, the products will be crafted in small, artisanal batches for optimal quality and made from premium California-grown cannabis.

Under the terms of the Agreement, Allied will contribute the Tactical Relief™ brand support including use of trademark, artwork, logos and package design for a series of products. On an ongoing basis, Allied will be financially responsible for all marketing design and support. Hollister will be responsible for all aspects of production and procurement of underlying materials. Hollister will also be responsible for all costs associated with distribution and sales support.  All production of cannabis products will take place under Hollister’s supervision and licenses. Allied and Hollister will further explore the development and marketing of additional products, as well as expanding into additional regions within the United States over the coming years.

The new Tactical Relief™ products will be distributed exclusively by Hollister’s distribution partner, Indus Holdings Inc. (CSE: INDS), and is anticipated to be in retail locations throughout California within quarter three of 2020. An estimated 5% of net profits from all sales will be donated to charity.  The remaining revenue generated from the sale of the products will be shared 60:40 between Hollister and Allied.

“This partnership is one that unites two powerful companies in the cannabis space with one common mission: to help veterans and first responders change the way they manage PTSD and TBI. This is a huge shift that has to happen nationwide. This partnership is the start of that shift,” said Adam Smith, VP Natural Health at Allied Corp.

Carl Saling, Hollister’s CEO stated: “We are thrilled to be working with Allied Corp. to bring much needed relief to our amazing veterans and 1st responders with PTSD and other ailments. This is a very important mission for Hollister to be able to have a huge impact on our veteran’s lives.”

About the Tactical Relief™  Brand

Led by a Green Beret and trainer of law enforcement, the Tactical Relief™ brand creates, promotes and sells high quality and patriotic CBD oils throughout the country. Allied’s CBD oils are full spectrum and are currently made from the highest quality hemp grown in Kentucky. Adam Smith (VP of Natural Health for Allied Corp.) is a Green Beret with nearly 17 years in service and experienced firsthand how CBD can help veterans and active-duty (military and first responders) ease their physical and mental stress due to post traumatic stress disorder and traumatic brain injury. Tactical Relief™ is on a mission to end the stigma around hemp and cannabis products, and to provide relief to as many service members as possible.

Website: https://tacticalrelief.com/

About Allied Corp.

Allied Corp. is an international medical cannabis production company with a mission to address today’s medical issues with a primary focus on Post Traumatic Stress Disorder in veterans and first responders. Allied helps those who have served by researching, developing and producing targeted cannabinoid health solutions for those who need them. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.

For more information on Allied Corp., visit www.allied.health

Investor Relations for Allied:
[email protected]
1-877-255-4337

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a California based vertically integrated cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality California-grown cannabis and hemp products. Hollister uses a vertically integrated, high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker.”

Website: www.hollistercannabisco.com

HOLLISTER BIOSCIENCES INC.:

Company Contact:

[email protected]
Tel: 604-961-0296

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Tags: , , , ,
Posted in All Recent Posts, Featured, Hollister Biosciences | Comments Off on Hollister Biosciences Inc. $HOLL.ca and Allied Corp. sign Definitive Agreement for Distribution of Products Under Veteran Based Brand: Tactical Relief™ $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

« Older Entries
Newer Entries »